Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia

Latest News

FDA approval stamp | Image Credit: Surendra - stock.adobe.com
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

November 15th 2024

Revumenib has been approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older.

Genes - CrazyJuke - stock.adobe.com
NUP98 Rearrangements Linked to Poor Outcomes in AML

November 15th 2024

FDA approval stamp | Image credit: BHM-stock.adobe.com
FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia

November 8th 2024

Tacrolimus | Image Credit: © MQ-Illustrations - stock.adobe.com
Tacrolimus Linked to Lower Acute GVHD Risk

November 7th 2024

New therapies for AML and other blood cancers may be informed by the overexpression of 3 proteins | image credit: jovannig - stock.adobe.com
New Work Highlights Proteins as Potential Novel AML Therapeutic Targets

November 2nd 2024

More News

Older man smiling with nurse | Image Credit: © Beaunitta Van Wyk/peopleimages.com - stock.adobe.com
April 17th 2024

Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate

Gayle Turim Dickstein
A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
AML| Image Credit: Dzmitry - stock.adobe.com
April 8th 2024

In AML, CAR T-Cell Therapy Has Higher CR Rate After Transplant

Jared Kaltwasser
In this investigation, investigators sought insights into the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy in acute myeloid leukemia (AML), with a particular focus on how various patient subgroups fared for complete remission (CR).
Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com
April 2nd 2024

Revumenib Earns FDA Priority Review in R/R KMT2Ar Acute Leukemia

Jordyn Sava
Revumenib, a first-in-class Menin inhibitor, was granted priority review from the FDA for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia.
Mom and child with cancer | Image Credit: photographee.eu - stock.adobe.com
April 2nd 2024

Post Treatment, Children With ALL Experience Long-Term Fatigue

Jared Kaltwasser
This new report helps clarify the ways in which the disease—and its treatment—affects the lives of children.
Diagnosis, Treatment Remain Challenges for Chronic Disseminated Candidiasis in Acute Leukemia
March 25th 2024

Diagnosis, Treatment Remain Challenges for Chronic Disseminated Candidiasis in Acute Leukemia

Luke Halpern
A case report of a patient with acute leukemia who developed chronic disseminated candidiasis revealed difficulties in diagnosing and treating the illness.
Concept of FDA approved | Image credit: wladimir1804 - stock.adobe.com
March 19th 2024

FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First-Line Ph+ ALL

Rose McNulty
The FDA has granted accelerated approval to ponatinib (Iclusig) plus chemotherapy for the first-line treatment pf Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
AML cells | Image credit: Laszlo - stock.adobe.com
March 17th 2024

Research Into Reactive Oxygen Species Could Help Address AML Treatment Resistance

Jared Kaltwasser
Treatment resistance remains a major challenge in the treatment of acute myeloid leukemia (AML), and leveraging actionable therapeutic targets is far from straightforward.
leukemia disease concept | Image credit: chrupka - stock.adobe.com
March 12th 2024

Case Series Highlights Bacillus Cereus Risk in Patients With AML, Neutropenia

Jared Kaltwasser
Introducing ciprofloxacin to their institution’s empiric antimicrobial regimen for patients with AML and prolonged or recurrent neutropenic fevers appeared to reduce the risk of Bacillus cereus infection.
AML representation | Image Credit: Andrey stock.adobe.com
March 6th 2024

Pediatric AML Preclinical Pipeline Boosted by Xenograft Models

Luke Halpern
Developing accurate predictive models for patients with pediatric acute myeloid leukemia (AML) can close the preclinical gap in treatment for the rare disease.
Spongy bone tissue affected by osteoporosis, 3D illustration | Image Credit: © Dr_Microbe - stock.adobe.com
February 26th 2024

Methotrexate—but Not Glucocorticoids—Affects BMD in Patients With ALL

Jared Kaltwasser
The findings add complexity to questions about the long-term impact of acute lymphoblastic leukemia (ALL) therapy.
Doctor holding child's hand with intravenous drip | Image Credit: © New Africa - stock.adobe.com
February 21st 2024

COVID-19–Related Chemotherapy Delays Common in Pediatric Patients With Acute Lymphoblastic Leukemia or Lymphoma

Luke Halpern
Despite the widespread practice of delaying or modifying chemotherapy treatment for patients with COVID-19, the investigators wrote that there are no clear data indicating the benefit of this practice.
Genomic Testing Is Worth the Wait When Balanced Against Cost of the Wrong Therapy
February 14th 2024

Genomic Testing Is Worth the Wait When Balanced Against Cost of the Wrong Therapy

Mary Caffrey
Coverage from the discussion, "Cancer Genomics: The Gateway to Access and Health Equity” on the first day of Patient-Centered Oncology Care 2023.
Vibrant abstract image of the world | Image credit: Tasnim - stock.adobe.com
February 14th 2024

Geographic, Sociodemographic Factors Significantly Influence AML in Elderly Patients

Gwen Mergian
Investigators analyzed global, national, and regional trends in acute myeloid leukemia (AML), which predominantly affects individuals aged 60 to 89 years.
Lonely sad girl hugging a soft teddy bear | Image credit: Pictures Paradise - stock.adobe.com
February 8th 2024

Research Indicates In Utero Origins of Acute Leukemia in Children

Luke Halpern
Circumstantial and direct evidence, including a review of twin and backtracking studies, demonstrate potential prenatal development of acute childhood leukemias.
Man holding AML word on wooden cube | Image Credit: Andrey-stock.adobe.com
January 31st 2024

In AML, Immunotherapy Shows Promise to Expand Treatment Toolbox

Jared Kaltwasser
Most of the research suggests combination therapies might be the best option for many patients who have acute myeloid leukemia (AML).
AML Acute Myeloid Leukemia | Image Credit: momius-stock.adobe.com
January 29th 2024

ELN Risk Category, MRD Status Predictive of Relapse in Patients With AML

Jared Kaltwasser
The study may help explain why some patients are more prone to relapse following a complete response to induction therapy, as indicated by measurable residual disease (MRD) status and 2017 European LeukemiaNet (ELN) criteria.
Blood cells flowing - Катерина Євтехова - stock.adobe.com
January 27th 2024

Increased Fatigue Associated With Greater Risk of Mortality Among Patients With AML, ALL, MDS

Rose McNulty
The findings suggest patient-reported outcomes—namely fatigue—may be helpful in identifying patients at a higher risk of death and other adverse outcomes but warrant further research.
ASH 2023: Coverage of ALL
January 20th 2024

ASH 2023: Coverage of ALL

Mary Caffrey
Selected coverage of acute lymphoblastic leukemia (ALL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12 2023, San Diego, California.
Findings Suggest Utility of Specialized MRD Testing in Management of FLT3-ITD AML With Quizartinib
January 5th 2024

Findings Suggest Utility of Specialized MRD Testing in Management of FLT3-ITD AML With Quizartinib

Mary Caffrey
Red Blood Cells - Design Cells stock.adobe.com
December 22nd 2023

alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden

Russ Conroy
Those with chronic graft-versus-host-disease who have received allogeneic hematopoietic stem cell transplant (alloHSCT) may experience enhanced graft-versus-leukemia effects, thus producing a lower relapse rate in acute myeloid leukemia.
Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com
December 8th 2023

Health Care Resource Use, Cost Burden Appear Substantial in R/R B-Cell ALL

Russ Conroy
Treatment with blinatumomab or inotuzumab ozogamicin particularly confers higher total costs for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Child laying in hospital bed | Image credit: wavebreak3 - stock.adobe.com.jpg
November 3rd 2023

High Disease Burden at Acute Leukemia Diagnosis More Common in Black Children, Study Finds

Rose McNulty
A study evaluating disparities among children with acute leukemia found that Black children are more likely to present with higher disease burden at diagnosis compared with non-Hispanic White children.
High LDH Levels Associated With Worse Survival in Newly Diagnosed AML
October 13th 2023

High LDH Levels Associated With Worse Survival in Newly Diagnosed AML

Russ Conroy
Elevated white blood cell counts also appear to correlate with shorter overall survival in patients receiving standard induction chemotherapy plus cytarabine for acute myeloid leukemia.
Blood cells | Image credit: flashmovie - stock.adobe.com
September 8th 2023

AML-Specific Early Mortality Risk Indices May Increase Accuracy of Care Quality Measurements

Rose McNulty
A study found acute myeloid leukemia (AML) salvage therapy was independently associated with early mortality compared with frontline therapy, suggesting that algorithms measuring quality of care should incorporate risk mortality indices that factor in disease characteristics and treatment status.
image of leukemia cell
August 29th 2023

Older Patients With AML Less Likely to Receive Genomic Testing, Study Finds

Pearl Steinzor
A study highlights an unmet need for patients with acute myeloid leukemia (AML) to access and afford genomic testing, especially among an older patient population.
<123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo